Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2020

09.09.2019 | Peritoneal Surface Malignancy

Shorter Survival of Patients with Upper-Third Gastric Cancer Preoperatively Diagnosed as Stage IA Compared with Those with Middle to Lower Lesions

verfasst von: Tatsuo Matsuda, MD, PhD, Manabu Ohashi, MD, PhD, Masahiro Tsujiura, MD, PhD, Satoshi Ida, MD, PhD, Koshi Kumagai, MD, PhD, Souya Nunobe, MD, PhD, Takeshi Sano, MD, PhD, Naoki Hiki, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Although preoperatively diagnosed stage IA (cT1N0) gastric cancer includes pathologically advanced disease, patients with cT1N0 middle- to lower-third gastric cancer (MLTG) experience favorable outcomes even if they undergo gastrectomy with limited lymph node dissection; however, whether this is true for upper-third gastric cancer (UTG) patients is unknown. In this study, we examined the survival of patients with cT1N0 UTG compared with patients with MLTG.

Methods

We retrospectively reviewed the data for 1707 consecutive patients with cT1N0 gastric cancer who underwent gastrectomy between 2006 and 2013. Patients were divided into the UTG or MLTG groups, and clinicopathological characteristics and survival were compared between the groups. Factors affecting survival were identified using multivariate analysis. Survival was calculated according to pathological findings.

Results

The patient group included 334 UTG patients and 1373 MLTG patients. The 5-year overall survival (OS) of UTG patients was significantly shorter than that of MLTG patients, and UTG was identified as an independent prognostic factor of cT1N0 gastric cancer. Among UTG cases, the OS of pT2–4 or pN1–3 was significantly shorter than that of pT1 or pN0 disease. No significant differences were found between such diseases in MLTG. All relapses in UTG were distant metastases.

Conclusions

cT1N0 UTG with pT2–4 or pN1-3 are prognostic indicators of shorter OS, although MLTG of either disease is associated with favorable prognosis. Thus, UTG is an independent prognostic factor in cT1N0 gastric cancer; however, limited dissection is acceptable for cT1N0 UTG because relapses occur at distant sites.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRef
2.
Zurück zum Zitat Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27.CrossRef Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27.CrossRef
3.
Zurück zum Zitat Japanese Gastric Cancer Treatment Guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19. Japanese Gastric Cancer Treatment Guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.
4.
Zurück zum Zitat Lee JH, Lee KN, Kim HI, Kim MG, Ha TK, Kwon SJ. Discordant findings between preoperative endoscopy and postoperative pathology as an independent prognostic factor in gastric cancer patients. Surg Endosc. 2016;30(7):2743–50.CrossRef Lee JH, Lee KN, Kim HI, Kim MG, Ha TK, Kwon SJ. Discordant findings between preoperative endoscopy and postoperative pathology as an independent prognostic factor in gastric cancer patients. Surg Endosc. 2016;30(7):2743–50.CrossRef
5.
Zurück zum Zitat Tsujiura M, Hiki N, Ohashi M, et al. Excellent long-term prognosis and favorable postoperative nutritional status after laparoscopic pylorus-preserving gastrectomy. Ann Surg Oncol. 2017;24(8):2233–40.CrossRef Tsujiura M, Hiki N, Ohashi M, et al. Excellent long-term prognosis and favorable postoperative nutritional status after laparoscopic pylorus-preserving gastrectomy. Ann Surg Oncol. 2017;24(8):2233–40.CrossRef
6.
Zurück zum Zitat Hiki N, Katai H, Mizusawa J, et al. Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG0703). Gastric Cancer. 2018;21(1):155–61.CrossRef Hiki N, Katai H, Mizusawa J, et al. Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG0703). Gastric Cancer. 2018;21(1):155–61.CrossRef
7.
Zurück zum Zitat Kim W, Kim HH, Han SU, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg. 2016;263(1):28–35.CrossRef Kim W, Kim HH, Han SU, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg. 2016;263(1):28–35.CrossRef
8.
Zurück zum Zitat Jang JH, Beron RI, Ahn HS, et al. Clinicopathological features of upper third gastric cancer during a 21-year period (Single Center Analysis). J Gastric Cancer. 2010;10(4):212–18.CrossRef Jang JH, Beron RI, Ahn HS, et al. Clinicopathological features of upper third gastric cancer during a 21-year period (Single Center Analysis). J Gastric Cancer. 2010;10(4):212–18.CrossRef
9.
Zurück zum Zitat Japanese Classification Of Gastric Carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12. Japanese Classification Of Gastric Carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12.
10.
Zurück zum Zitat Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRef Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRef
11.
Zurück zum Zitat Ichikawa D, Komatsu S, Kosuga T, et al. Clinicopathological characteristics of clinical early gastric cancer in the upper-third stomach. World J Gastroenterol. 2015;21(45):12851–6.CrossRef Ichikawa D, Komatsu S, Kosuga T, et al. Clinicopathological characteristics of clinical early gastric cancer in the upper-third stomach. World J Gastroenterol. 2015;21(45):12851–6.CrossRef
12.
Zurück zum Zitat Kunisaki C, Shimada H, Nomura M, et al. Surgical outcome in patients with gastric adenocarcinoma in the upper third of the stomach. Surgery. 2005;137(2):165–71.CrossRef Kunisaki C, Shimada H, Nomura M, et al. Surgical outcome in patients with gastric adenocarcinoma in the upper third of the stomach. Surgery. 2005;137(2):165–71.CrossRef
13.
Zurück zum Zitat Fujikawa H, Yoshikawa T, Hasegawa S, et al. Diagnostic value of computed tomography for staging of clinical T1 gastric cancer. Ann Surg Oncol. 2014;21(9):3002–7.CrossRef Fujikawa H, Yoshikawa T, Hasegawa S, et al. Diagnostic value of computed tomography for staging of clinical T1 gastric cancer. Ann Surg Oncol. 2014;21(9):3002–7.CrossRef
14.
Zurück zum Zitat Yamamoto S, Nishida T, Kato M, et al. Evaluation of endoscopic ultrasound image quality is necessary in endosonographic assessment of early gastric cancer invasion depth. Gastroenterol Res Pract. 2012;2012:194530.CrossRef Yamamoto S, Nishida T, Kato M, et al. Evaluation of endoscopic ultrasound image quality is necessary in endosonographic assessment of early gastric cancer invasion depth. Gastroenterol Res Pract. 2012;2012:194530.CrossRef
15.
Zurück zum Zitat Tokunaga M, Hiki N, Fukunaga T, Ohyama S, Yamada K, Yamaguchi T. Better prognosis of T2 gastric cancer with preoperative diagnosis of early gastric cancer. Ann Surg Oncol. 2009;16(6):1514–9.CrossRef Tokunaga M, Hiki N, Fukunaga T, Ohyama S, Yamada K, Yamaguchi T. Better prognosis of T2 gastric cancer with preoperative diagnosis of early gastric cancer. Ann Surg Oncol. 2009;16(6):1514–9.CrossRef
16.
Zurück zum Zitat Kano Y, Ohashi M, Ida S, et al. Oncological feasibility of laparoscopic subtotal gastrectomy compared with laparoscopic proximal or total gastrectomy for cT1N0M0 gastric cancer in the upper gastric body. Gastric Cancer. 2019;22(5):1060–8.CrossRef Kano Y, Ohashi M, Ida S, et al. Oncological feasibility of laparoscopic subtotal gastrectomy compared with laparoscopic proximal or total gastrectomy for cT1N0M0 gastric cancer in the upper gastric body. Gastric Cancer. 2019;22(5):1060–8.CrossRef
17.
Zurück zum Zitat Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.CrossRef Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.CrossRef
18.
Zurück zum Zitat Kurokawa Y, Matsuura N, Kimura Y, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015;18(4):691–7.CrossRef Kurokawa Y, Matsuura N, Kimura Y, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015;18(4):691–7.CrossRef
19.
Zurück zum Zitat Fan XS, Chen JY, Li CF, et al. Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population. World J Gastroenterol. 2013;19(21):3316–23.CrossRef Fan XS, Chen JY, Li CF, et al. Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population. World J Gastroenterol. 2013;19(21):3316–23.CrossRef
Metadaten
Titel
Shorter Survival of Patients with Upper-Third Gastric Cancer Preoperatively Diagnosed as Stage IA Compared with Those with Middle to Lower Lesions
verfasst von
Tatsuo Matsuda, MD, PhD
Manabu Ohashi, MD, PhD
Masahiro Tsujiura, MD, PhD
Satoshi Ida, MD, PhD
Koshi Kumagai, MD, PhD
Souya Nunobe, MD, PhD
Takeshi Sano, MD, PhD
Naoki Hiki, MD, PhD
Publikationsdatum
09.09.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07782-1

Weitere Artikel der Ausgabe 1/2020

Annals of Surgical Oncology 1/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.